Original Article

You have full text access to this OnlineOpen article

The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma

  1. Kyong-Hwa Park M.D., Ph.D.,
  2. In-Keun Choi M.D.,
  3. Seok-Jin Kim M.D., Ph.D.,
  4. Sang-Chul Oh M.D., Ph.D.,
  5. Jae-Hong Seo M.D., Ph.D.,
  6. Chul-Won Choi M.D., Ph.D.,
  7. Byung-Soo Kim M.D., Ph.D.,
  8. Sang-Won Shin M.D., Ph.D.,
  9. Yeul-Hong Kim M.D., Ph.D.,
  10. Jun-Suk Kim M.D., Ph.D.†,*

Article first published online: 11 APR 2005

DOI: 10.1002/cncr.21041

Issue

Cancer

Cancer

Volume 103, Issue 11, pages 2338–2343, 1 June 2005

Additional Information

How to Cite

Park, K.-H., Choi, I.-K., Kim, S.-J., Oh, S.-C., Seo, J.-H., Choi, C.-W., Kim, B.-S., Shin, S.-W., Kim, Y.-H. and Kim, J.-S. (2005), The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma. Cancer, 103: 2338–2343. doi: 10.1002/cncr.21041

Author Information

  1. Division of Oncology/Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea

  1. †

    Fax: (011) 82 28661643

*Division of Oncology/Hematology, Department of Internal Medicine, Korea University Guro Hospital, 97 Guro-dong-gil, Guro-ku, Seoul, 152-703, Korea

  1. †

    Fax: (011) 82 28661643

Publication History

  1. Issue published online: 18 MAY 2005
  2. Article first published online: 11 APR 2005
  3. Manuscript Accepted: 25 JAN 2005
  4. Manuscript Revised: 11 JAN 2005
  5. Manuscript Received: 10 NOV 2004

Funded by

  • Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea. Grant Number: 01-PG3-PG6-01GN07-0004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

REFERENCES

  • 1
    Li HM, Dou KF, Sun K, Gao ZQ, Li KZ, Fu YC. Palliative surgery for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2003; 2: 110–113.
  • 2
    Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003; 98: 1689–1700.
    Direct Link:
  • 3
    Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996; 7: 593–600.
  • 4
    Malka D, Boige V, Dromain C, Debaere T, Pocard M, Ducreux M. Biliary tract neoplasms: update 2003. Curr Opin Oncol. 2004; 16: 364–371.
  • 5
    Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984; 54: 965–969.
    Direct Link:
  • 6
    Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000; 23: 425–428.
  • 7
    Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998; 9: 653–656.
  • 8
    Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer. 1995; 31A: 1594–1598.
  • 9
    Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002; 13: 1192–1196.
  • 10
    Findlay M, Cunningham D, Norman A, et al. A Phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994; 5: 609–616.
  • 11
    Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol. 1998; 16: 2877–2885.
  • 12
    Muggia FM, Wu X, Spicer D, et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res. 1996; 2: 1461–1467.
  • 13
    Morizane C, Okada S, Okusaka T, Ueno H, Saisho T. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology. 2003; 64: 475–476.
  • 14
    Ho DH, Pazdur R, Covington W, et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 1998; 4: 2085–2088.
  • 15
    Mani S, Sciortino D, Samuels B, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17: 97–101.
  • 16
    Chen JS, Yang TS, Lin YC, Jan YY. A Phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol. 2003; 33: 353–356.
  • 17
    Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology. 2004; 66: 138–142.
View Full Article (HTML) Get PDF (109K)